title: The Insulin Resistance Intervention after Stroke trial: A perspective on future practice and research.
abstract: The prevention of recurrent events after ischaemic stroke and transient ischaemic attack is well established and based on lifestyle changes, antithrombotics, statins, antihypertensives and carotid surgery. The international IRIS trial assessed whether pioglitazone, a glucose-lowering insulin-sensitizing drug, would reduce recurrent vascular events in patients with ischaemic stroke or transient ischaemic attack. After 4.8 years, pioglitazone therapy was associated with reduced vascular events and new diabetes, and an increase in weight, oedema and bone fractures. Pioglitazone may add to the strategies for preventing further events in patients with stroke or transient ischaemic attack.
authors.affiliation: Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK Philip.bath@nottingham.ac.uk.
authors.forename: Philip M
authors.initials: PM
authors.lastname: Bath
authors.affiliation: Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.
authors.forename: Jason P
authors.initials: JP
authors.lastname: Appleton
authors.affiliation: Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.
authors.forename: Nikola
authors.initials: N
authors.lastname: Sprigg
mesh_terms: D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007333:Insulin Resistance; D002546:Ischemic Attack, Transient; D020521:Stroke
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: Prevention; clinical trial; ischaemic stroke; stroke; treatment; vascular events